Telix Pharmaceuticals (TLX) Liabilities and Shareholders Equity (2023 - 2025)
Telix Pharmaceuticals (TLX) reported Liabilities and Shareholders Equity of $1.2 billion for Q4 2025, up 17.38% year-over-year from $991.7 million in Q4 2024, and up 17.38% quarter-over-quarter from $991.7 million in Q4 2024.
Telix Pharmaceuticals (TLX) Liabilities and Shareholders Equity (2023 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $1.2 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | Telix Pharmaceuticals | 4.81 Bn | 4.67 Bn | - | 1.16 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.16 Bn |
| Dec 31, 2024 | 991.68 Mn |
| Dec 31, 2023 | 264.27 Mn |